Antonio
González Martín
Consultor Médico
Catholic University of the Sacred Heart
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Catholic University of the Sacred Heart (6)
2023
-
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
2021
-
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 12, pp. 1721-1731
2014
2013
-
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3831-3838